A C Buzaid
Overview
Explore the profile of A C Buzaid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Formozo A, Gomes J, Schmerling R, Buzaid A
J Skin Cancer
. 2021 Jul;
2021:5531864.
PMID: 34285817
Background: Checkpoint inhibitors are effective in the treatment of several types of cancer, either being used separately or in combination. Ipilimumab pioneered the treatment of metastatic melanoma, and nowadays, it...
2.
Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?
Bines J, Earl H, Buzaid A, Saad E
Ann Oncol
. 2014 Mar;
25(6):1079-85.
PMID: 24625452
Background: In early breast cancer, adjuvant chemotherapy decreases the risks of recurrence and breast cancer mortality, and neoadjuvant treatment leads to equivalent long-term outcomes. A large number of clinical trials...
3.
Tello M, Oliveira L, Parise O, Buzaid A, Oliveira R, Zanella R, et al.
Annu Int Conf IEEE Eng Med Biol Soc
. 2007 Nov;
2007:3524-7.
PMID: 18002757
The aim of this paper is to present the evaluations and results attained by our research group from the clinical applications of Electrochemical Therapy (EChT in short) on tumors, specifically...
4.
Buzaid A, Atkins M
Clin Cancer Res
. 2001 Sep;
7(9):2611-9.
PMID: 11555571
The combination of cisplatin-based chemotherapy with interleukin 2 (IL-2) and IFN-alpha, referred to as biochemotherapy or chemoimmunotherapy, has shown promising antitumor activity in patients with metastatic melanoma. Phase II studies...
5.
Balch C, Buzaid A, Soong S, Atkins M, Cascinelli N, Coit D, et al.
J Clin Oncol
. 2001 Aug;
19(16):3635-48.
PMID: 11504745
Purpose: To revise the staging system for cutaneous melanoma under the auspices of the American Joint Committee on Cancer (AJCC). Materials And Methods: The prognostic factors analysis described in the...
6.
Gershenwald J, Buzaid A, Ross M
Clin Lab Med
. 2001 Feb;
20(4):785-815.
PMID: 11221515
Although a standardized and uniformly accepted cancer staging system is an essential and fundamental requirement to enable meaningful comparisons across patient populations, the sometimes capricious biologic behavior of melanoma makes...
7.
Ekmekcioglu S, Ellerhorst J, Smid C, Prieto V, Munsell M, Buzaid A, et al.
Clin Cancer Res
. 2001 Jan;
6(12):4768-75.
PMID: 11156233
Despite recognition of the malignant potential of human melanomas, the mechanisms responsible for the pathobiological characteristics contributing to tumor growth, vascular invasiveness, and distant organ metastasis remain undefined. Recent studies...
8.
Buzaid A, Anderson C
Curr Oncol Rep
. 2000 Dec;
2(4):322-8.
PMID: 11122860
Cutaneous melanoma is a significant and increasing clinical problem. Knowing accurately the prognosis in a given patient is critical for treatment decisions and for optimal patient education. In this article...
9.
Grimm E, Smid C, Lee J, Tseng C, Eton O, Buzaid A
Clin Cancer Res
. 2000 Oct;
6(10):3895-903.
PMID: 11051235
Biochemotherapy, which combines traditional chemotherapy with immune modulating biologicals, produces an unexpectedly high response rate (>50%) in advanced melanoma patients. We hypothesize that immunological mechanism(s) are responsible for the increased...
10.
Gershenwald J, Fischer D, Buzaid A
Clin Plast Surg
. 2000 Aug;
27(3):361-76, viii.
PMID: 10941558
The identification of increasingly powerful prognostic factors has led to sequential modifications of the cutaneous melanoma staging system. Changes in the staging system are anticipated as more refined prognostic factors...